Pharmaceuticals Global On demand · 24-48h

Global Veterinary Immunization Market Strategic Research Report

Global Veterinary Immunization Market Strategic Research Rep…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Veterinary Immunization Market
$12.88B2025
9.5%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Livestock Vaccines (pigs, cattle, sheep, etc.), Poultry Vaccines (chickens, ducks, geese, etc.), Companion Animal Vaccines (dogs, cats, etc.), Aquaculture Vaccines (fish, shrimp, etc.)

By Application: Livestock Farms, Poultry Farms, Pet Clinics, Aquaculture Farms, Government Disease Control Agencies, Other

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Zoetis, Merck Animal Health, Boehringer Ingelheim Animal Health, Elanco, Ceva Santé Animale, Virbac, HIPRA, MSD Animal Health, Phibro Animal Health, Vetoquinol, IDT Biologika, Hester Biosciences, Indian Immunologicals Ltd, Huvepharma, Neogen Corporation, BioNet‑Asia, KBNP Inc., Vaxxinova, Guangdong Haid Group Co., Limited, China National Medicines Corporation Ltd., Harbin Pharmaceutical Group Co., Ltd., North China Pharmaceutical Group Corporation, Chengdu Kanghong Pharmaceutical Group Co., Ltd.

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 155 pages
Market size 2025
$12.88B
Billion USD
Forecast CAGR
9.5%
2025-2032
Forecast 2032
$24.3B
Projected
Области
5
Asia Pacific · Latin America · MEA · Europe · North America

Обзор

Scope of the Report

The global Veterinary Immunization market size is predicted to grow from US$ 12,881 million in 2025 to US$ 24,059 million in 2032; it is expected to grow at a CAGR of 9.5% from 2026 to 2032.

In 2025, global Veterinary Immunization approximately 470,252 k doses, with an average global market price of around US$ 28 per dose. Gross margin is about 47%. The cost is 15 usd. The Production is about 500,000 k doses. Veterinary Immunizations are biological products used to prevent and control diseases in animals by stimulating an immune response, thereby enhancing the animal's resistance to pathogens. These vaccines cover poultry, livestock, companion animals, and aquaculture species, and include inactivated vaccines, live-attenuated vaccines, subunit vaccines, and nucleic acid-based vaccines. They are widely used in livestock farming, pet health management, and overall animal disease control systems.

With the global population increasing and rising demand for animal protein, the livestock, poultry, companion animal, and aquaculture sectors will continue to drive demand for animal vaccines. The diversity of animal diseases, cross-species transmission risks, and restrictions on antibiotic use make vaccines a central component of disease prevention strategies. In the future, companies will focus on innovative vaccine technologies, including genetically engineered vaccines, subunit vaccines, viral vector vaccines, mRNA vaccines, and DNA vaccines, aiming to enhance immune response, extend protection duration, and reduce side effects.

Digital and intelligent farming management will enable more precise and personalized vaccination programs. IoT, sensors, and data analytics platforms allow real-time monitoring of animal health, disease risk, and immune status, enabling scientific determination of vaccination schedules, dosages, and combination strategies. This approach improves vaccine effectiveness, reduces farming risks, and supports large-scale management for industrial farms and veterinary institutions.

Moreover, global policy support for animal health, regulatory standardization, and vaccine certification systems will encourage more companies to invest in research, development, and market expansion. Multinational and domestic firms will strengthen collaboration through technology sharing, joint R&D, supply chain integration, and regional production layout to cover more animal species and regions. As the vaccine market becomes more international and standardized, the animal health vaccine industry chain will mature, elevating global animal health management, while simultaneously driving growth in biopharmaceuticals, vaccine manufacturing equipment, and digital agriculture services.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Veterinary Immunization market?

What factors are driving Veterinary Immunization market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Veterinary Immunization market opportunities vary by end market size?

How does Veterinary Immunization break out by Type, by Application?

This report presents a comprehensive overview of the global Veterinary Immunization market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Livestock Vaccines (pigs, cattle, sheep, etc.)
  • Poultry Vaccines (chickens, ducks, geese, etc.)
  • Companion Animal Vaccines (dogs, cats, etc.)
  • Aquaculture Vaccines (fish, shrimp, etc.)

Segment by Time

  • Short-term (<3 months)
  • Medium-term (3–12 months)
  • Long-term (>12 months)

Segment by Application

  • Livestock Farms
  • Poultry Farms
  • Pet Clinics
  • Aquaculture Farms
  • Government Disease Control Agencies
  • Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Veterinary Immunization market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Livestock Farms, Poultry Farms, Pet Clinics evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Veterinary Immunization Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 9.5%
Regional growth momentum
Market share by segment
Key metrics
Base value
$12.88B
2025
Forecast
$24.3B
2032
CAGR
9.5%
2025–2032
Области
5
global
Key companies
ZoetisMerck Animal HealthBoehringer Ingelheim Animal HealthElancoCeva Santé AnimaleVirbacHIPRAMSD Animal Health
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Livestock Vaccines (pigscattlesheepetc.)Poultry Vaccines (chickensducksgeeseetc.)Companion Animal Vaccines (dogscatsetc.)Aquaculture Vaccines (fishshrimpetc.)
By Application
Livestock FarmsPoultry FarmsPet ClinicsAquaculture FarmsGovernment Disease Control AgenciesOther

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Livestock Vaccines (pigs, cattle, sheep, etc.)
  • 3.1.3 Poultry Vaccines (chickens, ducks, geese, etc.)
  • 3.1.4 Companion Animal Vaccines (dogs, cats, etc.)
  • 3.1.5 Aquaculture Vaccines (fish, shrimp, etc.)
  • 3.1.6 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Livestock Farms
  • 4.1.3 Poultry Farms
  • 4.1.4 Pet Clinics
  • 4.1.5 Aquaculture Farms
  • 4.1.6 Government Disease Control Agencies
  • 4.1.7 Other
  • 4.1.8 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Zoetis
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Merck Animal Health
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Boehringer Ingelheim Animal Health
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Elanco
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Ceva Santé Animale
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Virbac
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 HIPRA
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 MSD Animal Health
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Phibro Animal Health
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Vetoquinol
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 IDT Biologika
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Hester Biosciences
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Indian Immunologicals Ltd
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Huvepharma
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Neogen Corporation
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 BioNet‑Asia
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 KBNP Inc.
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Vaxxinova
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 Guangdong Haid Group Co.,Limited
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 China National Medicines Corporation Ltd.
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
  • 8.21 Harbin Pharmaceutical Group Co., Ltd.
  • 8.21.1 Company Overview
  • 8.21.2 Key Products & Segments
  • 8.21.3 Financial Performance (2023–2025)
  • 8.21.4 Business Strategy
  • 8.21.5 SWOT Analysis
  • 8.21.6 Strategic Implications (2026–2032)
  • 8.22 North China Pharmaceutical Group Corporation
  • 8.22.1 Company Overview
  • 8.22.2 Key Products & Segments
  • 8.22.3 Financial Performance (2023–2025)
  • 8.22.4 Business Strategy
  • 8.22.5 SWOT Analysis
  • 8.22.6 Strategic Implications (2026–2032)
  • 8.23 Chengdu Kanghong Pharmaceutical Group Co., Ltd.
  • 8.23.1 Company Overview
  • 8.23.2 Key Products & Segments
  • 8.23.3 Financial Performance (2023–2025)
  • 8.23.4 Business Strategy
  • 8.23.5 SWOT Analysis
  • 8.23.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Veterinary Immunization market?
The global Veterinary Immunization market is estimated at US$ 12.88 billion in 2025 (base year) and is projected to reach US$ 24.06 billion by 2032.
How fast is the Veterinary Immunization market expected to grow?
The market is expected to grow at a CAGR of 9.5% from 2026 to 2032, expanding from US$ 12.88 billion in 2025 to US$ 24.06 billion in 2032, roughly 1.9 times its base-year value.
What does the Veterinary Immunization market cover?
In 2025, global Veterinary Immunization approximately 470,252 k doses, with an average global market price of around US$ 28 per dose. Gross margin is about 47%. The cost is 15 usd.
What are the main segments of the Veterinary Immunization market by type?
By type, the market is segmented into Livestock Vaccines (pigs, cattle, sheep, etc.), Poultry Vaccines (chickens, ducks, geese, etc.), Companion Animal Vaccines (dogs, cats, etc.) and Aquaculture Vaccines (fish, shrimp, etc.).
Which applications drive demand in the Veterinary Immunization market?
Key applications covered include Livestock Farms, Poultry Farms, Pet Clinics, Aquaculture Farms, Government Disease Control Agencies and Other.
Who are the key players in the Veterinary Immunization market?
Key players profiled include Zoetis, Merck Animal Health, Boehringer Ingelheim Animal Health, Elanco, Ceva Santé Animale, Virbac, HIPRA and MSD Animal Health, among 23 companies covered in total.
Which regions and countries are covered for Veterinary Immunization?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Veterinary Immunization market?
As the vaccine market becomes more international and standardized, the animal health vaccine industry chain will mature, elevating global animal health management, while simultaneously driving growth in biopharmaceuticals, vaccine manufacturing equipment, and digital agriculture services.
Who should buy the Veterinary Immunization market report?
The report is intended for manufacturers and solution providers, distributors and end users in Livestock Farms, Poultry Farms and Pet Clinics, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Veterinary Immunization market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from 3 500,00 $
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.